Primavera-escuddo trial

Ended Awarded Last action

Contract number
75N91019F00129
Awardee
Awarding agency
Obligated
$1,984,724

Award facts

Opportunity
Contract value 100% obligated
$1,984,724.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541720 Research and Development in the Social Sciences and Humanities
PSC
Q301 Reference Laboratory Testing
Set-aside
No set-aside
Competition
Full and Open Competition Sealed Bid
Pricing
Firm Fixed Price
Place of performance
Costa Rica

Award details come from SAM.gov/FPDS.

About this award

Written by GovTribe AI ·

The National Cancer Institute issued a delivery order to Fundacion Inciensa on February 28, 2019, with a ceiling value of $1,984,724, under a single-award Indefinite Delivery Contract for evaluation of single-dose protection afforded by prophylactic HPV vaccines under the PRIMAVERA-ESCUDDO trial.

Place of performance is Costa Rica. The order runs from March 1, 2019, through September 15, 2020. Work includes conducting clinical trials, collecting and analyzing data, performing laboratory testing, and evaluating vaccine efficacy. Pricing is firm fixed price with no set-aside designation.

Quick answers

Who was awarded contract 75N91019F00129?

75N91019F00129 was awarded to Fundacion Inciensa by National Cancer Institute (National Institutes of Health) on February 28, 2019.

How much is contract 75N91019F00129 worth?

The government has obligated $1,984,724 on 75N91019F00129.

Is contract 75N91019F00129 an order under another contract?

Yes. 75N91019F00129 is a delivery order under HHSN261201700012I, an indefinite delivery contract.

Was contract 75N91019F00129 competed?

The extent of competition for 75N91019F00129 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login